Oncology · Ovarian CancerTrial Updateclinicalmid-term

GSK's Mo-Rez Evaluated in 1L Maintenance for HRd Ovarian Cancer in BEHOLD-Ovarian03 Trial

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

GSK14 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/11/2026, 6:02:15 AM

Assessment confidence: 50% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The BEHOLD-Ovarian03 trial is critical as it evaluates a new treatment option for HRd ovarian cancer, which could significantly impact GSK's oncology portfolio. Positive outcomes may shift treatment paradigms and enhance competitive positioning against established therapies like bevacizumab. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 25 ranked evidence items (3 high-relevance).

Strategic Assessment

Positive results could enhance GSK's portfolio in oncology and provide a new treatment option for patients, potentially shifting treatment paradigms in HRd ovarian cancer. The strongest clinical anchor is Mo-Rez in First- Line (1L) Maintenance Treatment of Non- Homologous Recombination Deficient Ovarian Cancer (HRd OC) [BEHOLD-Ovarian03] (ClinicalTrials.gov), entity match (bevacizumab); patient population match (maintenance). In Oncology · Ovarian Cancer, 5 regulatory and 4 competitive items passed relevance filtering for GSK.

Competitive Pressure

The most relevant competitive pressure comes from Phase 3 Trial of SHR-8068, Adebrelimab, and Bevacizumab in Hepatocellular Carcinoma (Humanexa Signals) — entity match (bevacizumab). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial positions GSK's Mo-Rez as a potential competitor to existing therapies in the HRd ovarian cancer space, particularly against bevacizumab, which is a standard treatment.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Moderate corpus alignment. Relevant agencies in corpus: FDA, MHRA. The trial results will inform potential regulatory submissions, impacting the approval timeline and market entry for Mo-Rez as a new treatment option.

Key Risks

Elevated medium regulatory exposure for GSK could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, Mo-Rez could capture market share from existing therapies, potentially increasing GSK's revenue in the oncology sector.
Upside for GSK may improve if Mo-Rez in First- Line (1L) Maintenance Treatment of Non- Homologous Recombination Deficient Ovarian Cancer (HRd OC) [BEHOLD-Ovarian03] (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Oncology · Prostate Cancer · Trial Update · If successful, this combination could enhance Merck's position in the prostate cancer treatment market, competing directly with existing therapies.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and safety data, as well as any regulatory submissions following the trial outcomes.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Mo-Rez in First- Line (1L) Maintenance Treatment of Non- Homologous Recombination Deficient Ovarian Cancer (HRd OC) [BEHOLD-Ovarian03]
ClinicalTrials.govhigh relevance
Entity match (bevacizumab); Patient population match (maintenance)
FDA document
View source
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Phase 3 Trial of SHR-8068, Adebrelimab, and Bevacizumab in Hepatocellular Carcinoma
Humanexa Signalshigh relevance
Entity match (bevacizumab)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalsmedium relevance
Sponsor/company relevance (Pfizer)
Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival
Humanexa Signalsmedium relevance
Sponsor/company relevance (Merck)

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedhigh relevance
Patient population match (first line)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Folate receptor-targeted PEGylated PLGA nanoparticles for the site-specific delivery of hesperidin in epithelial ovarian cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Polyploid giant cancer cells: the hidden players in ovarian cancer progression and prognosis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison FT-IR spectral fingerprints of kidney Cancer in urine and serum: Clinical correlations and diagnostic potential.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

GSK
bevacizumab

Commercial impact

medium

If successful, Mo-Rez could capture market share from existing therapies, potentially increasing GSK's revenue in the oncology sector.

Regulatory impact

medium

The trial results will inform potential regulatory submissions, impacting the approval timeline and market entry for Mo-Rez as a new treatment option.

What to watch

Monitor trial results and safety data, as well as any regulatory submissions following the trial outcomes.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.